Injecting a peptide, whether a licensed weight-loss pen or a compound bought online, is a small clinical procedure, and small clinical procedures still carry real risks if they are done without the right product, technique or support. This guide sets out what actually makes an injectable safe, the infection and injection-site problems patients need to recognise, how to report a suspected side effect through the UK's official reporting scheme, and where the regulated route differs from the grey market.
Licensed vs unlicensed injectables
Some of the most widely used injectable medicines in the UK today are peptides. Wegovy (semaglutide) and Mounjaro (tirzepatide) are both peptide-based weight-management medicines, and both hold a UK marketing authorisation from the MHRA. That authorisation means the manufacturing process, the sterility of the pen, the accuracy of every dose and the safety data behind the product have all been independently assessed before the medicine reaches a patient.
Away from that licensed market, a large grey market sells peptides such as BPC-157, TB-500 and various growth hormone secretagogues, usually labelled "research use only" to sidestep the fact that they are not approved medicines. Our guide to whether peptides are legal in the UK covers the regulatory position in more detail, and our comparison of licensed versus online-sold weight-loss peptides looks specifically at that market. The practical safety difference is straightforward: a licensed pen has a known, tested content and a manufacturer accountable for it; an unlicensed vial does not, and nobody has verified what is actually inside it.
That gap shows up at every stage of use. A licensed manufacturer must prove batch-to-batch consistency, sterility and stability before a product is ever approved, and continues to be inspected against those standards afterwards. A seller of an unlicensed peptide is under no such obligation, so two vials bought from the same listing can differ in strength, purity or even identity. For a patient drawing up a dose at home, that uncertainty is not a minor technicality: it is the difference between a known, tested dose and a genuine guess.
Infection and injection-site risks
Any injection breaches the skin, so basic technique matters whatever is being injected. Wash your hands before you start, clean the injection site, use a new sterile needle for every injection, and never share a pen, vial or needle with anyone else, even briefly. Sharing injecting equipment carries a real risk of transmitting blood-borne viruses such as hepatitis B, hepatitis C or HIV, on top of the more everyday risk of skin infection.
Rotating injection sites (moving between the abdomen, thigh or upper arm rather than using the same spot every time) helps avoid lumps, bruising and a skin change called lipohypertrophy that can affect how a medicine is absorbed. With licensed pens, the needle and delivery mechanism are designed and tested for safe patient use. With unlicensed peptides, patients are typically reconstituting freeze-dried powder themselves and drawing it up with separately sourced syringes and diluent, which multiplies the points at which non-sterile technique can introduce bacteria. Our guide to reconstituting peptides at home looks at that process in detail.
Signs something is wrong
Some redness or a small bruise straight after an injection is common and usually settles within a day or two. What needs attention is redness or swelling that gets worse rather than better, spreads outward from the injection site, or comes with warmth, increasing pain, a red streak tracking up the limb, pus or other discharge, or a fever. These are signs of a possible skin or soft-tissue infection, and they need prompt assessment by a GP, pharmacist or NHS 111 rather than a wait-and-see approach.
Separately, watch for signs of an allergic reaction: a widespread rash, swelling of the lips, face or throat, or difficulty breathing shortly after an injection. These are medical emergencies and need immediate care by calling 999. If you have injected an unlicensed product and develop concerning symptoms, tell whoever treats you exactly what was injected, since that information changes how they can help you.
Knowing which service to use matters too. Mild redness that is not spreading can often wait for a routine GP or pharmacist appointment. Worsening infection signs, a persistent fever, or general uncertainty about a reaction are a reason to call NHS 111 for guidance the same day. Breathing difficulty, facial or throat swelling, or any sign of a severe, rapidly worsening reaction need a 999 call and emergency care, not a wait-and-see approach at home.
Reporting via the Yellow Card scheme
The MHRA runs the Yellow Card scheme, the UK's system for reporting suspected side effects and safety incidents involving medicines, medical devices and, importantly, unlicensed or unregulated products too. Anyone can submit a report directly at yellowcard.mhra.gov.uk, not just doctors and pharmacists: patients and carers can report a suspected reaction themselves, in their own words, without needing a clinician to do it for them.
Reporting matters for two reasons. For licensed medicines, Yellow Card reports feed into the ongoing safety monitoring that continues long after a product is approved, helping regulators spot patterns that clinical trials were too small to detect. For unlicensed peptides, formal pharmacovigilance barely exists at all, since these products sit outside the licensing system that normally generates and reviews safety data, so a patient report may be one of the only records that a problem occurred at all. If something goes wrong after any injection, licensed or not, a Yellow Card report is a genuinely useful thing to file.
Safer regulated routes
The regulated route removes most of the failure points described above in one step. A licensed pen arrives with a known, tested concentration, a sterile single-use needle system, and a patient information leaflet setting out exactly how and where to inject. Prescribing comes with a dose-escalation schedule where relevant, guidance on managing common side effects, and a clinician who can be contacted if something does not seem right, none of which exists when a peptide is bought from an online seller with no prescriber attached.
None of this replaces good technique: even with a licensed pen, hand hygiene, site rotation and safe sharps disposal in a proper sharps bin (never a household bin) still matter. But it does mean that if a problem does arise, there is a known product, a documented dose and a clinical team already involved, rather than a patient working out alone what was actually injected and at what strength. If you are weighing up an injectable treatment, whether for weight management or another condition, a free consultation with a UK-registered clinician is the place to start.